Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Mapping the Disease: Specialized Imaging and Biomarkers

At a Glance

The 68Ga-DOTATATE PET/CT is the gold standard scan for mapping neuroendocrine neoplasms, using a radioactive tracer to pinpoint tumor locations. Doctors combine this advanced imaging with biomarker tests like Chromogranin A and 5-HIAA to track tumor activity and guide your treatment plan.

Accurately “mapping” a neuroendocrine neoplasm (NEN) requires more than just standard hospital scans. Because these tumors are biologically unique, doctors use specialized imaging that looks for specific “docking stations” on the tumor cells, combined with blood and urine tests that track the chemicals the tumors release.

The Gold Standard: DOTATATE PET/CT

For many years, the standard for imaging NENs was the “OctreoScan.” However, technology has advanced significantly. The current “gold standard” for staging most NENs is the 68Ga-DOTATATE PET/CT (or similar SSTR-targeted PET scans) [1][2].

How it Works: The Lock and Key

Most well-differentiated neuroendocrine cells have Somatostatin Receptors (SSTRs) on their surface [3].

  • The “Key”: The scan uses a tiny amount of a radioactive tracer (the DOTATATE) that acts like a key.
  • The “Lock”: When injected, this tracer travels through your body and “locks” onto the SSTRs (the locks) on the tumor cells [3][4].
  • The Result: The PET scanner detects where these “keys” have gathered, creating a highly detailed map of even very small or hidden tumors that standard CT scans might miss [1][5].

What to Expect: During the scan, you will receive the tracer through an IV, wait about 45 to 60 minutes for it to circulate and “lock” onto the tumors, and then lie still in the PET scanner for 20 to 30 minutes.

This scan is so effective that it changes the treatment plan for about 1 in 3 patients by finding disease that was previously unknown [6][7].

Tracking the Disease: Key Biomarkers

Biomarkers are substances found in your blood or urine that can reflect how active the tumor is.

1. Chromogranin A (CgA)

Chromogranin A is a protein produced by almost all neuroendocrine cells [8]. While it is a common tool for monitoring NENs, it is not perfect.

  • False Positives: Common medications like Proton Pump Inhibitors (PPIs) (e.g., omeprazole) used for acid reflux can cause CgA levels to spike even when no cancer is present [9][10].
  • Other Factors: Kidney or liver disease can also lead to elevated CgA levels [11]. Because of these issues, current guidelines are increasingly cautious about using CgA as a definitive marker [12][13].

2. 24-Hour Urinary 5-HIAA

If you have a “functional” tumor that produces serotonin, your doctor will likely order a 5-HIAA test [14]. 5-HIAA is the waste product created when your body breaks down serotonin [15].

  • Why 24 Hours?: Serotonin levels can fluctuate throughout the day. Collecting urine over a full 24-hour period provides an average of the total serotonin produced, which is more accurate than a single “spot” check [16].
  • Dietary Restrictions: You must avoid certain serotonin-rich foods (like bananas, walnuts, and avocados) for 24–48 hours before and during the test, as they can cause a false-high reading [17].

Putting it All Together

Imaging and biomarkers work as a team. The DOTATATE PET/CT shows where the disease is, while markers like 5-HIAA can show how active the functional symptoms might be [8][15]. Together, they help your medical team decide when to start treatment, when to change it, and how well it is working.

Common questions in this guide

Why do I need a DOTATATE PET/CT scan instead of a standard CT?
Standard CT scans can miss very small or hidden neuroendocrine tumors. A DOTATATE PET/CT uses a specialized tracer that locks onto specific receptors on tumor cells, creating a highly detailed map of the disease that often changes treatment plans.
What can cause an elevated Chromogranin A (CgA) level besides a tumor?
Common acid reflux medications known as proton pump inhibitors (PPIs) can cause Chromogranin A (CgA) levels to spike even when no cancer is present. Kidney or liver disease can also lead to falsely elevated CgA levels.
Why must I avoid certain foods before a 5-HIAA urine test?
The 5-HIAA test measures the breakdown of serotonin in your urine. Eating serotonin-rich foods like bananas, walnuts, and avocados before or during the test can cause a false-high reading and inaccurate results.
What should I expect during a DOTATATE PET/CT scan?
After receiving the tracer through an IV, you will wait 45 to 60 minutes for it to circulate and lock onto the tumors. Following this, you will lie still in the PET scanner for 20 to 30 minutes to complete the imaging.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why are you ordering a 68Ga-DOTATATE PET/CT instead of a standard CT or MRI?
  2. 2.What was the SSTR expression level on my pathology report, and how does it affect my PET scan results?
  3. 3.If my Chromogranin A (CgA) level is elevated, could it be due to my acid reflux medication (PPIs) or another health condition?
  4. 4.Is a serum (blood) 5-HIAA test an option for me, or is the 24-hour urine collection necessary for accuracy?
  5. 5.How often will we repeat these biomarkers and scans to monitor my treatment response?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

    Deppen SA, Liu E, Blume JD, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016; (57(5)):708-14 doi:10.2967/jnumed.115.163865.

    PMID: 26769865
  2. 2

    Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

    Crown A, Rocha FG, Raghu P, et al.

    Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

    PMID: 31853990
  3. 3

    Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.

    Ambrosini V, Zanoni L, Filice A, et al.

    Cancers 2022; (14(4)) doi:10.3390/cancers14041055.

    PMID: 35205805
  4. 4

    Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis.

    Alevroudis E, Spei ME, Chatziioannou SN, et al.

    Cancers 2021; (13(8)) doi:10.3390/cancers13081813.

    PMID: 33920195
  5. 5

    68Ga-DOTATATE PET/CT Compared with 131I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors.

    Shahrokhi P, Emami-Ardekani A, Harsini S, et al.

    Asia Oceania journal of nuclear medicine & biology 2020; (8(1)):8-17 doi:10.22038/aojnmb.2019.41343.1280.

    PMID: 32064278
  6. 6

    Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

    Calais J, Czernin J, Eiber M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

    PMID: 28473600
  7. 7

    The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

    Skoura E, Michopoulou S, Mohmaduvesh M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016; (57(1)):34-40 doi:10.2967/jnumed.115.166017.

    PMID: 26471695
  8. 8

    Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

    Pavel ME, Phan AT, Wolin EM, et al.

    The oncologist 2019; (24(4)):463-474 doi:10.1634/theoncologist.2018-0217.

    PMID: 30355775
  9. 9

    Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center.

    Butler OL, Mekhael MM, Ahmed A, et al.

    Frontiers in endocrinology 2020; (11()):606264 doi:10.3389/fendo.2020.606264.

    PMID: 33391185
  10. 10

    Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An example.

    van Balveren JA, Erdem-Eraslan L, Verboeket-van de Venne WPHG, et al.

    Clinica chimica acta; international journal of clinical chemistry 2022; (530()):99-103 doi:10.1016/j.cca.2022.03.013.

    PMID: 35306022
  11. 11

    Challenges with Validating Nonharmonized Assays.

    Hackenmueller SA

    The journal of applied laboratory medicine 2019; (4(1)):1-3 doi:10.1373/jalm.2019.029272.

    PMID: 31639700
  12. 12

    Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.

    Chauhan A, Chan K, Halfdanarson TR, et al.

    CA: a cancer journal for clinicians 2024; (74(4)):359-367 doi:10.3322/caac.21840.

    PMID: 38685134
  13. 13

    Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.

    Meng QH, Halfdanarson TR, Bornhorst JA, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(24)):5559-5567 doi:10.1158/1078-0432.CCR-24-1875.

    PMID: 39453770
  14. 14

    Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.

    Massironi S, Gallo C, Franchina M, et al.

    Expert review of gastroenterology & hepatology 2025; (19(10)):1119-1132 doi:10.1080/17474124.2025.2557245.

    PMID: 40902188
  15. 15

    BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

    Mirakhur B, Pavel ME, Pommier RF, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0296.

    PMID: 30084687
  16. 16

    Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection.

    Calanchini M, Tadman M, Krogh J, et al.

    Endocrine connections 2019; (8(8)):1082-1088.

    PMID: 31265996
  17. 17

    Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers.

    Algeri L, Falkman L, Spada F, et al.

    ESMO open 2024; (9(11)):103959 doi:10.1016/j.esmoop.2024.103959.

    PMID: 39442478

This page explains diagnostic imaging and biomarker testing for neuroendocrine neoplasms for educational purposes. Always consult your oncology team to interpret your specific scan and lab test results.

Get notified when new evidence is published on Neuroendocrine neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.